Introduction
Recombinant adenovirus provides one of the most promising delivery vectors for gene therapy, and is particularly suitable for gene therapy of cancer. The virus can accommodate significant amounts of exogenous DNA, infects cells readily independent of cell cycle and can be routinely produced to high titre. Most cancer deaths involve metastatic disease, however, and the development of adenovirus vectors capable of targeting disseminated cancer cells following intravenous injection is an important priority. This requires considerable improvement in existing delivery technology.
A prerequisite to gene therapy of metastatic cancer is that the virus must gain access to disseminated tumour cells, and this requires an extended circulation time in the plasma without depletion through infection of nontarget cells. Such selectivity would also improve the safety of the approach. Preventing unwanted uptake is not trivial, however, since type 5 adenovirus binds cells via at least three different interactions; the knob domain of fibre binds the Coxsackie and Adenovirus Receptor (CAR), 1 the RGD motif of the penton base binds avb3 and avb5 integrins 2 and the fibre protein binds to heparan sulphate glycosaminoglycans (HSGs). 3, 4 These receptors are widely expressed on many cell types, 5 usually allowing ready infection of nontarget cells. Following intravenous injection to mice, adenovirus is cleared rapidly from the bloodstream into the liver, severely restricting its access to peripheral targets. Uptake into hepatocytes is thought to be mediated by the binding interactions described above and several strategies have been examined to prevent rapid hepatic uptake, mainly by using genetic modification of virus tropism. Alemany and Curiel 6 and Leissner et al 7 examined clearance from the murine bloodstream using a virus with its CAR-binding activity ablated, and observed that both the unmodified and the CAR binding-ablated virus showed rapid uptake into the liver. Similarly, Einfeld et al 8 demonstrated that viruses with both CAR-binding and integrin-binding ablated were still taken rapidly into the liver, albeit with slightly slower kinetics. Smith et al 9, 10 showed that hepatic infection could be CAR independent, and implicated the shaft portion of the fibre protein in mediating hepatic uptake, suggesting that the conventional two-stage entry pathway may be an oversimplification. The pathways of liver uptake are clearly complex and probably contain a level of redundancy under normal conditions. Producing genetically modified vectors to evade all of these uptake mechanisms is a major technical challenge.
Apart from active hepatic infection, uptake of adenovirus into the liver can also result from phagocytosis by Kupffer cells and other phagocytes. This route of uptake can also severely deplete the level of circulating virus, further inhibiting attempts to gain access to extra-hepatic target cells. There are suggestions, however, that phagocytic capture may be saturable. For example, Tao et al   11 showed that increasing virus dose began to saturate uptake into Kupffer cells, leading to proportionately greater levels of hepatocyte transduction. It follows that manipulating the dose of a virus engineered to avoid active hepatic infection might also overcome phagocytic capture.
In this paper, we have examined a polymer-coating methodology to overcome all known types of hepatic uptake. We hypothesized that surface masking of adenovirus using a multivalent reactive polymer based on poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA) should provide a physical barrier to prevent all forms of receptor-mediated infection, while the administration of elevated doses of the polymer-coated virus (pc-virus) might begin to saturate mechanisms of phagocytic liver capture. Combining these approaches could enable extended plasma circulation time of the virus and provide access to disseminated target cells. We present data supporting this hypothesis, achieving plasma circulation of viable pc-virus (pc-virus) with initial half-life of approximately 30 min. This provides the first step to a platform for systemic delivery of adenovirus to many widespread and disseminated cellular targets.
Results

Comparison of methods to measure pharmacokinetics of adenovirus in vivo
Measurement of the biodistribution kinetics of adenovirus in vivo requires careful technical consideration. Measurement of infectivity of blood and tissue samples ex vivo does not detect virus that has already infected cells, while the use of physical tracing techniques is likely to be confounded by the presence of noninfectious material in the preparation since typical adenovirus preparations have particle-to-infectivity ratios in the range of 10-100. Measurement of the distribution of tropism-ablated virus (eg pc-virus) is even more difficult, since ex vivo infectivity assays cannot detect tropismablated virus even when it is free in the plasma. We therefore sought to use a physical tracing technique and compared results obtained using quantitative (real time) polymerase chain reaction (Q-PCR) and 125 I-radiotracing with those using ex vivo sample infectivity to measure the blood clearance of unmodified adenovirus following intravenous injection. This comparison was then used to select our preferred labelling technique for measuring pc-virus. All studies were performed using double CsClbanded, DNAse-treated virus preparations.
To ensure that the radioactivity represented only intact adenovirus, free 125 I-iodide was removed from the preparation by size exclusion chromatography. Figure  1a shows that the virus (detected using pico green fluorescence to monitor virus DNA) elutes in the void volume of the Sepharose 4B column while free 125 I-iodide elutes much later, with no contamination of the virus preparation. The specific radioactivity of the virus was 4-8 Â 10 6 DPM/mg. To check that the iodination procedure had not damaged the virus, luciferase reporter expression in A549 cells was compared before and after radiolabelling and no difference was observed (Figure 1b) .
Plasma clearance curves measured using 125 I-iodidelabelled virus were compared with those determined by Q-PCR and infectivity analysis of recovered blood samples following intravenous injection to Balb/c mice (1 Â 10 9 virus particles (VP) of AdCMV-Luc/mouse). Figure 2 represents the data plotted on a linear scale with the insert showing the same data on a log scale. The infectivity analysis shows that infective virus is rapidly cleared from the plasma, with less than 0.025% remaining after 30 min. The data generated using Q-PCR are reasonably similar, with less than 1% of the input dose detected in plasma after 30 min. In contrast, however, the clearance profile obtained using radiolabelled virus is much higher at all time points and there is an extended Based upon these findings, we adopted Q-PCR analysis for determination of virus distribution in subsequent experiments. Some caution in interpretation of Q-PCR results is nevertheless required since there is a minor component of noninfective material determined by Q-PCR. This component may be particularly important in affecting analyses of virus levels less than 1-2% of the input dose.
Effect of dose on plasma circulation and biodistribution of adenovirus and pc-virus
The effect of intravenous dose on plasma clearance was assessed for unmodified virus and pc-virus at doses of 1 Â 10 9 , 1 Â 10 10 , 1 Â 10 11 , 4 Â 10 11 and 6 Â 10 11 VP/mouse. Figure 3a illustrates the plasma clearance curves obtained from each treatment group. The pc-virus shows markedly improved plasma circulation compared with the unmodified virus, with approximately 10-fold more pc-virus remaining in the circulation after 30 min at each dose examined. This is likely to result from the absence of receptor-mediated cell entry pathways for the pcvirus. 12 There is also an obvious dose effect, with higher doses of both normal virus and pc-virus showing greater fractional persistence in the plasma over the time course examined. This may reflect saturability of nonspecific clearance pathways, notably scavenging by Kupffer cells. 11 Plasma levels of virus and pc-virus measured 30 min after intravenous injection are shown in Figure 3b . The effects of ablation of active infection mechanisms and saturation of clearance pathways is again evident. At the highest dose examined (6 Â 10 11 VP/mouse), the pc-virus showed plasma levels of 47% after 30 min, compared with less than 5% for the unmodified virus. The area under the plasma-concentration curve (AUC) is elevated approximately 3.5-fold over the period 0-30 min, and this differential would be expected to increase over longer time periods. Analysis of total blood-borne virus showed that pc-virus is predominantly free in the plasma for all doses (data not shown). This is essential to facilitate its ready access to target cells, particularly target cells outside the blood stream, and the extended plasma circulation of viable virus provides a useful platform to enable access of the pc-virus to disseminated target sites.
Analysis of virus distribution in the major organs showed that the majority of virus was detectable in the liver for all treatment groups (Figure 4a ), consistent with its known hepatic uptake following intravenous delivery. Notably, however, the liver levels of pc-virus were lower than for unmodified virus at all doses examined. This is consistent with ablation of active infection mechanisms 9 VP/mouse) was administered intravenously and blood samples were analysed for radioactivity (closed squares), viral DNA (by Q-PCR using whole blood, closed diamonds) and infectivity (open circles). Data are expressed as % of input dose. The main graph compares the clearance curves on a linear scale while the insert uses a log scale.
Plasma circulation time, toxicity of polymer-coated adenovirus NK Green et al for the pc-virus decreasing uptake into the liver. Increasing virus dose also led to lower levels of hepatic uptake, consistent with saturability of Kupffer cell scavenging mechanisms. At the highest dose of pc-virus examined, liver levels accounted for only just over 50% of the pc-virus detected. These data allow calculation of liver:plasma ratios, which provide an indication of the efficiency of hepatic uptake from the circulation. For unmodified virus at relatively low doses, the liver:plasma ratio is over 1000, while for optimized formulations of pc-virus it falls to less than 1. Virus dose also influenced the distribution into the spleen. At low doses splenic uptake was very small (o1% of the virus recovered), although was greater at higher doses. Most notably the pc-virus, administered at 4 Â 10 11 VP/mouse, showed over 20% associated with the spleen after 30 min (Figure 4b ). These data raise the possibility that saturation of nonspecific uptake into the liver may lead to increased accumulation in secondary phagocytic sites -notably the spleen. There is also a suggestion of dose-related deposition in the lung, although this was not consistent and showed no clear pattern (Figure 4c ). These findings are compatible with the possibility that spleen and lung have uptake mechanisms for virus, although they only exert a significant effect on biodistribution when the liver fails to mediate complete removal of virus from the circulation.
Absence of liver transduction for pc-adenovirus
Following intravenous injection of unmodified adenovirus (10 9 VP/mouse), high levels of reporter gene expression were detectable in liver homogenates after 24 h ( Figure 5 ). In contrast, following administration of an equivalent dose of pc-virus, transgene expression in the liver was reduced more than 10 000 times to background levels. When the experiment was repeated using a higher dose of virus (6 Â 10 11 VP/mouse), we observed that the polymer-coating strategy still reduced hepatic transgene expression over 100-fold. These results clearly demonstrate that polymer coating significantly reduces hepatic transduction in vivo. Together with the extended plasma circulation of pc-virus described above, and the facility for receptor-specific retargeting, 12 this technology provides a platform for gaining receptormediated infection of disseminated target cells without the complication of high level hepatic transduction. 11 VP/mouse) were administered i.v. and transgene expression was measured after 24 h. While unmodified virus showed high levels of hepatic transgene expression (up to 10 9 RLU/liver), transgene expression mediated by pc-virus was 100-10 000-fold lower. Difference was assessed using unpaired t-test; Po0.05 (*), Po0.01 (**), Po0.001 (***); no significance ( w )
Decreased toxicity of pc-adenovirus
Mice treated with a high dose (6 Â 10 11 VP/mouse) of normal E1,E3-deleted virus appeared unwell after 24 h, with starey coat, decreased activity and some weight loss (Figure 6a ). In contrast, animals treated with an equivalent dose of pc-virus showed no obvious physical or behavioural changes. Hepatotoxicity was quantified by measurement of plasma transaminase levels, routinely used as markers of liver damage, 24 h following intravenous injection of a high dose (6 Â 10 11 VP/mouse) of unmodified virus or pc-virus. Measurement of transaminases in mice receiving unmodified virus was frequently confounded by an unexpected tendency of the blood to haemolyse; nevertheless, where they could be measured, levels of plasma transaminases were dramatically increased compared to control mice; in contrast, mice receiving pc-virus at the same dose showed no elevation of plasma transaminases. Figure 6b shows levels of alanine aminotransferase (ALT), and very similar results were obtained with aspartate aminotransferase (AST; not shown). There was also an obvious difference in physical properties between livers from the two groups of animals. Livers from mice that received pc-virus showed normal physical properties, while those from animals receiving unmodified virus were more friable and tended to disintegrate upon handling.
Discussion
In this study, we have used Q-PCR to demonstrate that unmodified adenovirus particles are lost from the plasma rapidly following intravenous injection to mice, in accord with previous data indicating that the bloodstream half-life of infectious adenovirus is less than 2 min. 6, 7 Following intravenous administration of 10 9 VP, less than 0.1% of the injected dose remains in the plasma after 30 min. At higher virus dose (6 Â 10 11 particles), the value is increased to approximately 5%, although the removal is still rapid. These plasma clearance kinetics offer very little opportunity for the virus to gain access to peripheral targets, effectively prohibiting the intravenous route for systemic delivery of adenovirus.
The predominant route of clearance from the murine bloodstream of intravenously administered virus is into the liver. 13 Receptor-mediated infection of hepatocytes and phagocytic scavenging by Kupffer cells are both likely to contribute to this rapid hepatic uptake, although these mechanisms will have different kinetics and capacities. For example, Tao et al used adenovirus labelled with the fluorophore Cy3 to show efficient Kupffer cell scavenging of relatively low doses of adenovirus (up to 3 Â 10 10 VP/mouse), but found that higher virus doses began to saturate this pathway. 11 It follows that the slight dose-dependent extension of circulation of unmodified virus observed in the present study may also reflect saturation of the Kupffer cell phagocytosis pathway, leading to increased amounts of virus in the bloodstream and elevated accumulation in spleen and lungs.
Several groups are attempting to prevent hepatic uptake of adenovirus, either by genetic modification of the adenovirus cell-binding domains [14] [15] [16] or by physical shielding of the virus surface using hydrophilic polymers. 12, 17, 18 The former approach is challenging, in view of the large number of hepatic uptake pathways that can lead to adenovirus infection, and we have therefore focused on exploring physical masking of the virus surface to ablate all receptor-mediated interactions simultaneously. Q-PCR was selected as the methodology of choice to monitor biodistribution of the tropismablated PHPMA-coated adenovirus, and separate standard curves (using spiked homogenates) were constructed for each of the tissues and viruses analysed to enable accurate quantitation.
Masking the adenovirus surface with multivalent PHPMA leads to substantially extended circulation in the bloodstream compared to unmodified virus, with a plasma circulation profile that suggests loss of the highaffinity uptake pathways that may normally correspond to receptor-mediated hepatic infection. As with unmodified virus, there is a clear dose dependence of the extended plasma circulation of pc-virus, indicating that it can still be captured by nonspecific mechanisms such as phagocytosis. Taken together, these data suggest that ablating receptor-mediated infection of hepatocytes can be combined with the saturation of Kupffer cell scavenging to yield marked extensions in the circulation of tropism-ablated pc-adenovirus.
In the murine bloodstream, pc-virus is found predominantly in the plasma fraction, not associated with red cells, and this is essential to maximize its access to extravascular targets. The observation that type 5 Of the animals treated with unmodified virus, one had excessive haemolysis that prevented ALT determination while four others showed readings that were off scale (42400 IU/l) and were included as values of 2400 IU/l in the analysis. Similar results were obtained for aspartate aminotransferase (data not shown). Difference was assessed using unpaired t-test; Po0.05 (*), Po0.01 (**), Po0.001 (***); no significance ( w ).
Plasma circulation time, toxicity of polymer-coated adenovirus NK Green et al adenovirus binds extensively to human erythrocytes, 19 a phenomenon not seen in mice, raises an important issue for extravasation of adenovirus following intravenous administration in clinical trials. Our studies have shown that over 90% of a therapeutic dose of type 5 adenovirus is sequestered by human erythrocytes under physiological conditions ex vivo, but that pc-virus shows 10-fold decreased binding (Lyons et al, submitted for publication), which may improve bioavailability of the virus following intravenous injection to patients.
Intravenous injection of pc-virus resulted in 100-10 000-fold less hepatic transgene expression than shown by unmodified virus, compatible with ablation of receptor-mediated pathways of hepatic infection. This observation that CMV promoter-driven expression is much depleted in the liver demonstrates an important feature of pc-viruses, namely that the use of tissueselective promoters to avoid unwanted transcription of therapeutic genes may not be necessary, particularly if cell-specific transductional targeting is efficient. It also suggests that toxicities due to hepatic replication of conditionally replicating (or even fully replication competent) adenoviruses should be minimized using the polymer coating approach to prevent the initial infection. Indeed, avoidance of hepatocyte infection may also decrease hepatic inflammation arising in any subsequent cell-based response against virus capsid proteins. The effects observed here, using polymer coating to decrease hepatotoxicity measured as serum transaminases and general animal condition, were obtained using a simple E1, E3-deleted reporter virus. When the polymer-coating technology is applied to delivery of anticancer viruses that encode proteins mediating potent cytotoxic mechanisms, it is likely that the ability to prevent unwanted infection will mediate even greater decreases in liver toxicity as well as providing protection for a range of other sensitive cells and tissues.
There has been relatively little study of adenovirus distribution kinetics in humans and the majority of clinical data has been obtained from trials using the conditionally replicating ONYX 015 virus, administered by hepatic artery infusion for the treatment of metastatic colorectal cancer 20 and intravenously for the treatment of metastatic lung tumours. 21 No viral DNA was detectable by Q-PCR in plasma after 6 h following hepatic artery injection 20 although low levels (approx. 0.3% of the dose) were detectable 6 h after the end of intravenous highdose virus infusion (2 Â 10 12 VP/person) with a clearance half-life of approximately 20 min. 21 We would expect the basic principles of using polymer coating to obviate unwanted infection should be applicable in humans as well as mice, and on this basis would expect to be able to extend the circulation time in humans considerably, improving access of the virus to disseminated tumour cells and simultaneously decreasing toxicities mediated through unwanted infection of nontarget cells.
Polymer-coating technology appears to provide a platform for development of targeted intravenous adenovirus gene therapy in a range of disease settings. The approach is simple and gentle, and polymer coating could be useful for masking the surface of other microorganisms and even cells for diverse applications in medicine and other fields.
Materials and methods
Cell culture and virus production
Type 5 adenovirus E1-expressing human embryonic 293 cells and A549 human lung carcinoma cells (obtained from the American Type Culture Collection) were grown in Dulbeccos modified Eagle's medium (DMEM) containing 20 mM HEPES, 10% foetal calf serum (FCS) and 2 mM glutamine. Adenovirus infections were carried out in DMEM containing 20 mM HEPES, 2% FCS and 2 mM glutamine (infection medium).
Adenovirus AdCMV-Luc is an E1, E3-deleted Ad5 recombinant expressing luciferase (Luc) under control of the CMV promoter that was used throughout this study. Virus stocks were propagated in 293 cells, purified by banding on a CsCl gradient, and treated with Benzonase nuclease (Novagen, Merck Biosciences, Nottingham, UK), to remove contaminating DNA prior to purification on a second CsCl gradient. The purified virus was dialysed against PBS (pH 7.8) containing glycerol (10% v/v), MgCl 2 and CaCl 2 (each 100 mg/l). Viral particle numbers were determined using the Pico Green DNA assay, 22 calibrated against a standard curve using lambda DNA, and infectivity was measured by plaque assay on 293 cells. Particle:Infectivity (P:I) ratios ranged from 9 to 95 for all virus stocks.
Preparation of 125 I-labelled adenovirus
An iodobead (Perbio Science UK, Tattenhall, Cheshire) iodination reagent was washed with phosphate-buffered saline (PBS), then allowed to air dry. The bead was transferred to a 1.5 ml Eppendorf tube containing 200 ml of PBS and 100 mCi of radioactive iodine (IMS30-Amersham, Bucks, UK). The mixture was left at room temperature for 5 min, then 800 ml of double-banded virus (2 Â 10 11 VP/ml) was added and the reaction was allowed to proceed for another 15 min at room temperature. At the end of the incubation period, the iodobead was removed to terminate the reaction. The radiolabelled virus was purified using gel purification chromatography through a Sepharose 4B column (Pharmacia Biotech). Fractions were collected and analysed for radioactivity in an automatic gamma counter (Packard Cobra) and viral DNA was measured using the Pico Green DNA assay.
Virus infectivity assays
Cells were seeded into 96-well plates at 10 4 cells/well and infected 24 h later with 10 3 particles/cell of virus, in 100 ml infection medium. The cells were harvested after 48 h. For measurement of luciferase activity, cells were lysed in Promega reporter lysis buffer (100 ml), lysate (20 ml) was transferred to each well of a black 96-well plate, 'Brightglow luciferase assay reagent' (100 ml, Promega, Southampton UK) was added to each well and the plate measured in a Wallac Victor 2 multilabel counter. Uninfected cells were used as a negative control and values were expressed as relative luminescence units (RLU). Levels of infectious virus in blood samples (see below) were determined by infecting A549 cells in 96-well plates with 20 ml of whole blood that had been diluted to 100 ml in adenovirus infection medium. After 90 min, an additional 100 ml of infection medium was added to 12 VP/ml in HEPES/PBS, pH 7.8) was mixed with reactive PHPMA bearing reactive 4-nitrophenyl (ONp) esters on pendent diglycyl sidechains, prepared as previously described. 23 Under these conditions, in excess of 90% of primary amino groups on the surface of the virus become modified by the polymer. 12 The reaction was allowed to proceed at room temperature overnight, ensuring that all residual ONp esters were removed by hydrolysis.
In vivo experimentation
Female BALB/c mice were obtained from the Biomedical Services Unit, John Radcliffe Hospital, Oxford, UK. All mice were pathogen free and aged 6-8 weeks at the commencement of experimental procedures. Procedures were in accordance with the guidelines produced by the UK Coordinating Committee on Cancer Research (UKCCCR) and were performed with the authority of Home Office Project and Personal Licences.
For kinetics studies, mice were anaesthetized using Hypnorm (0.2 ml/kg)/Hypnoval (1 mg/kg) and virus samples were injected into the tail vein using a 29-gauge insulin syringe (Becton Dickinson, Oxford, UK). Blood samples were taken from the tail vein into heparinized capillary tubes at 2, 5, 10 and 30 min after the virus injection. After 30 min, the animals were culled, organs harvested and frozen in liquid nitrogen. A blood volume corresponding to 2.0 ml/mouse was assumed for calculation of virus present in the bloodstream.
For measurement of plasma transaminases, mice were anaesthetized as above and injected intravenously with 6 Â 10 11 VP/mouse. They were killed after 24 h and plasma transaminases (ALT and AST) were measured by a commercial contractor (Covance UK) in lithium heparin-treated plasma samples.
Radioactivity measurements
Biodistribution of radioactivity was measured by homogenization of organs in Promega lysis buffer (Promega, Southampton, UK) using a motor-driven teflon on glass homogeniser, with analysis of geometry-standardized 1 ml samples of blood and organ homogenates in a Packard Cobra well-type gamma counter.
Purification of DNA for Q-PCR analysis
DNA was extracted from blood (cells and plasma separately, except for Figure 2 ) and organs to enable determination of virus content by Q-PCR. Heparinized blood samples (20 ml) were diluted to 200 ml with PBS and centrifuged (5000 rpm, 15 min) to separate the plasma from erythrocytes. Supernatants were removed and further diluted to 200 ml with PBS. Cell pellets were washed by resuspending in 200 ml of PBS and repelleting, the supernatants were removed and the cell pellets resuspended in 200 ml of PBS. Organs were homogenized using a motorized Teflon-on-glass homogenizer in Promega lysis buffer. DNA was extracted from the plasma, blood cell pellets and a 200 ml sample of tissue lysate using the Qiagen QIAamp DNA mini kit (Qiagen UK, Crawley, west Sussex, UK) according to the manufacturer's instructions. The purified DNA was eluted from the Qiagen column in 200 ml of elution buffer (AE buffer), and 5 ml was used in each Q-PCR reaction.
Quantitative PCR analysis
Quantitative PCR (Q-PCR) was used to detect the presence of adenovirus DNA in extracted DNA samples using an ABI 5700 Sequence Detection System and software. Amplification of an 84 bp fragment of the Adenovirus Fibre gene was carried out using the primers 5 0 TGGCTGTTAAAGGCAGTTTGG 3 0 and 5 0 GCACTC CATTTTCGTCAAATCTT 3 0 with detection of amplified sequences by a Taqman probe (5 0 TCCAATATCTGGAA CAGTTCAAGTGCTCATCT 3 0 ), which was labelled at the 5 0 end with the FAM fluorophore and at the 3 0 end with the TAMRA quencher. Primers and probe were purchased from Sigma Genosys (Pampisford, Cambridgeshire, UK). Reactions were carried out in a total volume of 25 ml in ABI Taqman Master mix (Applied Biosystems, Warrington, Cheshire, UK) containing primers and probes at concentrations of 1.0 and 0.1 mM, respectively. All non-DNA-containing components were UV irradiated for 15 min prior to reactions being set up in a sterile environment. Thermocycling parameters were optimized as 2 min at 501C, 10 min at 951C followed by 40 cycles of 951C (30 s) and 601C (2 min). Analysis of data was carried out using the software provided and test samples compared to standards of known viral content based on pico green analysis. Standard curves were prepared for individual tissue types by spiking serial dilutions of virus into control tissues and extracting DNA for Q-PCR analysis as described above. Data were presented either as absolute numbers of viral particles, as % injected dose ( Figure 5 ) or as % recovered virus, to correct for injection variation. Virus recovery by Q-PCR was always within 65-120% of the intended dose.
Determination of luciferase expression in the liver
To determine the ability of viruses and PHPMA-coated viruses to mediate transgene expression in the liver, virus was administered intravenously to Balb/c mice (1 Â 10 9 -6 Â 10 11 VP/mouse) and animals were culled after 24 h. The liver was homogenised in Promega lysis buffer and luciferase gene expression measured using the 'Brightglow' reagent.
